Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation

Marvin M van Luijn; Martine E D Chamuleau; Gert J Ossenkoppele; Arjan A van de Loosdrecht; S Marieke van Ham

doi:10.4161/onci.1.2.18100

Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation

Oncoimmunology. 2012 Mar 1;1(2):211-213. doi: 10.4161/onci.1.2.18100.

Authors

Marvin M van Luijn¹, Martine E D Chamuleau, Gert J Ossenkoppele, Arjan A van de Loosdrecht, S Marieke van Ham

Affiliation

¹ Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center; Amsterdam, The Netherlands ; Department of Immunopathology; Sanquin Research and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam, The Netherlands.

Abstract

In this overview, we discuss the role of class II-associated invariant chain peptide (CLIP) in acute myeloid leukemia (AML), one of the few tumors expressing HLA class II. The clinical impact, function and regulation of CLIP expression on leukemic cells is addressed, indicating its potential as immunotherapeutic target in AML.